The University of Chicago Header Logo

Connection

Daniel Arber to Myeloproliferative Disorders

Back to Details
This is a "connection" page, showing publications Daniel Arber has written about Myeloproliferative Disorders.
Daniel Arber
Connection Strength
7.531
Myeloproliferative Disorders
  1. Classification of Myelodysplastic, Myeloproliferative, and Myelodysplastic/Myeloproliferative Neoplasms: The Past, Present, and Future. Am J Hematol. 2025 Jun; 100 Suppl 4:5-15.
    View in: PubMed
    Score: 0.796
  2. Guide to the Diagnosis of Myeloid Neoplasms: A Bone Marrow Pathology Group Approach. Am J Clin Pathol. 2023 10 03; 160(4):365-393.
    View in: PubMed
    Score: 0.721
  3. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228.
    View in: PubMed
    Score: 0.670
  4. Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. Am J Hematol. 2022 05; 97(5):514-518.
    View in: PubMed
    Score: 0.645
  5. Myelodysplastic/myeloproliferative neoplasms: are morphology and immunophenotyping still relevant? Best Pract Res Clin Haematol. 2020 06; 33(2):101139.
    View in: PubMed
    Score: 0.555
  6. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 05 19; 127(20):2391-405.
    View in: PubMed
    Score: 0.429
  7. STAT3 mutations are present in aggressive B-cell lymphomas including a subset of diffuse large B-cell lymphomas with CD30 expression. Haematologica. 2014 Jul; 99(7):e105-7.
    View in: PubMed
    Score: 0.376
  8. Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT. Blood. 2025 May 29; 145(22):2561-2573.
    View in: PubMed
    Score: 0.202
  9. Multihit TP53 Mutations in Myeloproliferative Neoplasms and Acute Myeloid Leukemia: Comparative Analysis of Survival and Risk Factors in 142 Informative Cases. Am J Hematol. 2025 Jun; 100(6):1010-1018.
    View in: PubMed
    Score: 0.199
  10. Evolution of WHO diagnostic criteria in "Classical Myeloproliferative Neoplasms" compared with the International Consensus Classification. Blood Cancer J. 2025 Mar 04; 15(1):31.
    View in: PubMed
    Score: 0.199
  11. TP53 Mutations in Myeloproliferative Neoplasms: Context-Dependent Evaluation of Prognostic Relevance. Am J Hematol. 2025 Apr; 100(4):552-560.
    View in: PubMed
    Score: 0.197
  12. Predictors of clinical outcome in myeloproliferative neoplasm, unclassifiable: A Bone Marrow Pathology Group study. Am J Clin Pathol. 2024 Sep 03; 162(3):233-242.
    View in: PubMed
    Score: 0.192
  13. Pathology of the myeloproliferative diseases. Hematol Oncol Clin North Am. 2003 Oct; 17(5):1101-27.
    View in: PubMed
    Score: 0.180
  14. The international consensus classification of eosinophilic disorders and systemic mastocytosis. Am J Hematol. 2023 08; 98(8):1286-1306.
    View in: PubMed
    Score: 0.176
  15. Clinicopathologic characteristics of myeloproliferative neoplasms with JAK2 exon 12 mutation. Leuk Res. 2023 04; 127:107033.
    View in: PubMed
    Score: 0.172
  16. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study. Mod Pathol. 2023 03; 36(3):100016.
    View in: PubMed
    Score: 0.171
  17. Advances in myelodysplastic/myeloproliferative neoplasms. Virchows Arch. 2023 Jan; 482(1):69-83.
    View in: PubMed
    Score: 0.170
  18. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022 11 24; 140(21):2228-2247.
    View in: PubMed
    Score: 0.170
  19. International Consensus Classification for myeloid neoplasms at-a-glance. Am J Hematol. 2023 01; 98(1):6-10.
    View in: PubMed
    Score: 0.169
  20. The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms. Am J Hematol. 2023 01; 98(1):166-179.
    View in: PubMed
    Score: 0.168
  21. Updates on eosinophilic disorders. Virchows Arch. 2023 Jan; 482(1):85-97.
    View in: PubMed
    Score: 0.167
  22. EAHP 2020 workshop proceedings, pediatric myeloid neoplasms. Virchows Arch. 2022 Oct; 481(4):621-646.
    View in: PubMed
    Score: 0.165
  23. Lymphoid blast transformation in an MPN with BCR-JAK2 treated with ruxolitinib: putative mechanisms of resistance. Blood Adv. 2021 09 14; 5(17):3492-3496.
    View in: PubMed
    Score: 0.156
  24. Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group. Mod Pathol. 2018 05; 31(5):690-704.
    View in: PubMed
    Score: 0.121
  25. A novel TRIP11-FLT3 fusion in a patient with a myeloid/lymphoid neoplasm with eosinophilia. Cancer Genet. 2017 Oct; 216-217:10-15.
    View in: PubMed
    Score: 0.116
  26. Template for Reporting Results of Biomarker Testing of Specimens From Patients With Myeloproliferative Neoplasms. Arch Pathol Lab Med. 2016 Jul; 140(7):675-7.
    View in: PubMed
    Score: 0.105
  27. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009 Jul 30; 114(5):937-51.
    View in: PubMed
    Score: 0.066
  28. STAT5B mutations in myeloid neoplasms differ by disease subtypes but characterize a subset of chronic myeloid neoplasms with eosinophilia and/or basophilia. Haematologica. 2024 06 01; 109(6):1825-1835.
    View in: PubMed
    Score: 0.047
  29. Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome. Haematologica. 2017 08; 102(8):1352-1360.
    View in: PubMed
    Score: 0.029
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.